STOPGAP II — a national randomized clinical trial for patients with stage 4 gastric cancer
What starts at UCI Health can help shape the national conversation.
-
1
STOPGAP II is a national randomized clinical trial for patients with stage 4 gastric cancer and peritoneal carcinomatosis.
-
2
The trial is a continuation of STOPGAP I, which was led by UCI Health and focused on younger patients with advanced gastric cancer.
-
3
STOPGAP I established safety and feasibility, paving the way for the national expansion of the study.
-
4
The trial is supported by the UC Irvine Anti-Cancer Challenge and is currently accruing participants ahead of expectations.
-
5
STOPGAP II aims to test a new treatment approach that could potentially change the treatment paradigm for gastric carcinomatosis.
